Background: because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely hospitalised older patients. Methods: this multi-centre, double-blind, stratified, block randomised, placebo-controlled trial was conducted at six Dutch hospitals. Patients age ≥70 years, acutely admitted through the emergency department for general medicine or surgical specialties and at risk for delirium were randomised (n = 245) to haloperidol or placebo 1 mg orally twice-daily (maximum of 14 doses) on top of standard nonpharmacological prevention strategies. The primary outcome was delirium incidence. Other endpoints included delirium severity and duration, drug safety and clinical outcomes. Results: intention-to-treat analysis included 242 participants (calculated sample size n = 390, statistical power of current sample 59%) allocated to haloperidol (n = 118) or placebo (n = 124). In the haloperidol and placebo group, delirium incidence was 19.5 versus 14.5% (OR 1.43, 95% CI 0.72 to 2.78); median (IQR) delirium duration 4 (2, 5) versus 3 (1, 6) days (P = 0.366); maximum DRS-R-98 score 16 (9.8, 19.5) versus 10 (5.5, 22.5) (P = 0.549; 53.7% missing data); hospital LOS 7 (4, 10.3) versus 7 (5, 11.8) days (P = 0.343); 3-month mortality 9.9 versus 12.5% (OR 0.77, 95% CI 0.34 to 1.75), respectively. No treatment-limiting side effects were noted.
Introduction
Delirium [1] is a frequent problem in acute clinical settings and may occur in up to 37% and 51% of older acute medical [2] and hip-fracture [3] admissions, respectively. Older patients who develop delirium experience more functional dependency and are at greater risk for institutionalisation and death [2, 4, 5] , underlying the importance of adequate delirium prevention.
Although multicomponent delirium prevention strategies that target orientation, circadian rhythm, early mobilisation, maintaining optimal fluid and nutritional status are effective in reducing delirium incidence [6, 7] , implementation and adherence challenges remain [8] . Studies examining the efficacy of pharmacological interventions to prevent delirium have demonstrated contradicting results [9] . Haloperidol is currently the drug of choice for treatment of delirium symptoms [10, 11] . Although there is a growing interest in the use of haloperidol for delirium prevention, evidence is limited and on the basis of current studies no definite conclusions can be drawn on its effectivity in general in-hospital older patients [12] .
We therefore aimed to assess the efficacy of prophylactic haloperidol in lowering delirium incidence in a population of older, acutely admitted, medical and surgical patients. Secondary aims were to assess its safety and impact on clinical outcomes.
Materials and methods

Trial design
The 'Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients (HARPOON)' study is a multi-centre, double-blind, stratified, block randomised, placebo-controlled trial. Participants were recruited between November 2012 and March 2015 at one university [VU University Medical Centre, (VUmc), Amsterdam] and five Dutch teaching hospitals. The study protocol was published previously [13] . The study was approved by the certified Medical Ethics Committee of VUmc, participating sites and the national competent authority. ' Apotheek Haagse Ziekenhuizen' was responsible for manufacturing, processing and packaging the verum and placebo haloperidol tablets in accordance with Good Manufacturing Practice guidelines and provided the randomisation schemes and blinding. Trial monitoring was independently performed by certified members of the Clinical Research Bureau and Data Safety Monitoring Board (DSMB). The DSMB reviewed blinded data for patient safety at regular time intervals during the study period. The study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. The trial was registered with clinicaltrials.gov (NCT01530308).
Participants
Eligible patients were aged ≥70 years, acutely hospitalised through the emergency department (ED) for a medical (gastroenterology, geriatrics, internal medicine, nephrology, pulmonology) or surgical specialty (colorectal-, general-, trauma-or vascular surgery, orthopaedics and urology) and at risk for delirium. Three sites only enroled non-surgical patients.
Baseline delirium risk was evaluated with the delirium risk assessment tool included in the Dutch Safety Management Programme (Veiligheidsmanagementsysteem, VMS), a nationally implemented in-hospital screening programme developed to identify vulnerable older patients on admission to prevent adverse outcomes [14] . The VMS delirium risk assessment tool consists of three questions, score ≥1 out of 3 denotes an increased risk for developing delirium.
Patients were approached within 24 h of admission by a research team member. All included patients provided written informed consent after reading the patient information leaflet and verbal explanation of the study. In case of graphomotor inability, oral informed consent was obtained in the presence of an independent adult witness (usually a close relative) who then signed on the patient's behalf. Exclusion criteria have been described in detail in the published protocol [13] .
Randomisation and interventions
Eligible and consenting patients were randomly assigned to placebo or haloperidol 1 mg tablets twice-daily at 12 noon and 8 pm for a maximum of seven consecutive days (total of 14 doses). This dose was based on regular oral starting dose for delirium treatment [10] and dose used in a previous study [15] . The 7-day intervention period was chosen to cover the days patients were most at risk for new-onset delirium [16] . Treatment assignment was performed in a blind manner using fixed randomisation schemes per site with a block size of 4 (1:1) stratified according to wellknown risk factors for hospital-associated delirium (age 70-79 or ≥80 years; planned surgery on admission or not). An electronic study medication prescription label was created to facilitate and enhance protocol adherence.
Placebo and haloperidol tablets were identical in appearance and packaged in identical unit-dose blister packs in cardboard boxes with sequentially numbered labels, each with an unique study identification number. Emergency unblinding was possible by 24 h contact with an on-call pharmacist in case delirium developed or when knowledge of treatment assignment could influence patient care. Study staff, clinicians and participants were to remain blinded throughout the study.
Outcomes
The primary outcome was delirium incidence within seven consecutive days following initiation of the study intervention. Secondary outcomes were delirium duration and severity; adverse events; QTc interval changes; ICU admission; hospital length of stay (LOS); post-discharge 3 and 6-month (new) institutionalisation, unplanned readmissions and mortality.
Data collection
Patient interviews and assessments were performed by trained clinicians and investigators. Baseline data collection included questionnaires, demographic and health-related characteristics. Medical history data were collected by medical chart review and used to assess the ICD-10 Charlson Comorbidity Index (CCI) [17] . The Six Item Cognitive Impairment Test (6CIT) was chosen as a measure for cognitive function [18] . The 16-item Dutch version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE-N) was used to evaluate changes in cognitive function over the previous 10 years [19] . Functional ability was assessed by patient-reported Katz Index of Independence in Activities of Daily Living (Katz ADL) [20] .
Delirium presence at baseline was based on clinical assessment by experienced clinicians or investigators. During the study intervention period, delirium presence and duration was based on structured daily patient observations supplemented by reviewing medical notes and nursing records for evidence of delirium symptoms. Nursing records included three times daily care observations and the 13-item Delirium Observation Screening Scale (DOSS) scores [21] , with average daily scores of ≥3 indicating possible delirium. Delirium diagnosis was confirmed by a clinician or an investigator according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for delirium [22] . All delirium cases were retrospectively verified by the local principal investigator by reviewing patient records before unblinding. The Delirium Rating Scale Revised 98 (DRS-R-98) was to be used to assess delirium severity and duration [23] . However, due to incomplete observations there was >50% missing DRS-R-98 data and therefore could not be reliably used. Hence, additional data were used as surrogate markers, including total daily DOSS scores [24] and open-label haloperidol treatment.
Participants were contacted by telephone 3 and 6 months post-discharge. These interviews were supplemented by medical chart reviews to collect data on living situation, mobility, hospital readmissions and mortality.
Safety was monitored throughout the study. Daily observations and examinations by clinicians and investigators as well as patient reports were used to assess adverse events.
Standard 12-lead electrocardiograms (ECGs) were recorded at predefined time-points before and during the study period (day 2, 4 and end) when possible. These time-points were based on oral haloperidol T 1/2 (12-38 h) and steadystate plasma concentrations (4-5 times T 1/2 ).
Sample size
Sample size calculation was based on the assumption that delirium incidence in the placebo group would be 20% and haloperidol prophylaxis would result in an absolute risk reduction of 10%. The estimate of delirium incidence in the placebo group was based on previously reported delirium incidences in surgical populations of 16.5% [15] to 32.5% [25] . To detect a significant difference between groups, 195 patients were required per treatment arm to give 80% statistical power at a two-sided 5% significant level (alpha).
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics version 22. Descriptive statistics (mean ± standard deviation (SD)), median and interquartile range (IQR) or frequency and percentage were used to describe basic patient characteristics. Statistical analyses were performed according to the intention-to-treat (ITT) principle, including all randomised patients except those for whom consent was missing. Patients who did not develop delirium during the study intervention period (total of 7 days or less for example due to hospital discharge or in-hospital death) were regarded negative on the primary outcome.
Delirium incidence rates are based on the number of participants diagnosed at least once with delirium (present or absent) within the first 7 days after initiation of study intervention. Delirium incidence was compared between groups using chi-squared test. Odds ratios (ORs) together with their 95% confidence intervals (CIs) are reported as effect size. When reporting effect sizes, the placebo group was taken as the reference group. A discrete-time survival analyses (DTSA) was performed to compare delirium incidence during follow-up while taking into account censoring of patients due to for example discharge or in-hospital death. Comparison of secondary outcomes between treatment groups was done using chi-squared test or Fisher's exact test for dichotomous and nominal outcomes, using independent-samples t-test for normally distributed continuous outcomes and Mann-Whitney U-test for ordinal outcomes and continuous outcomes that were not normally distributed. Histograms and Q-Q plots were used to assess whether the data were normally distributed. P-values <0.05 are considered statistically significant.
Results
Enrolment and baseline data
Study inclusion ran from November 5, 2012 to March 1, 2015. Last patient follow-up was completed on October 13, 2015. Due to limited financial and human resources the trial was ended before the anticipated sample size was reached.
245 participants were randomly assigned to haloperidol (n = 119) or placebo (n = 126). Three participants were excluded (1 haloperidol and 2 placebo patients) because of revoked or missing consent. The remaining 242 participants were available for ITT analysis of the primary outcome (118 haloperidol and 124 placebo patients). A total of 137 participants (56.6%) were alive Figure 1 . Study flow diagram. *Only numbers for the largest participating centre are provided, total numbers of eligible patients presenting in the acute care chain at the other participating hospitals were not available.
and available for 3-and 6-month follow-up (Figure 1) . Notable study population characteristics are presented in Table 1 .
Primary outcome
Delirium incidence in the haloperidol and placebo group was 19.5 versus 14.5% (OR 1.43, 95% CI 0.72 to 2.78; P = 0.302), respectively ( Table 2) . DTSA also demonstrated a higher statistically non-significant difference in the haloperidol group compared to placebo, with an OR comparable to the primary analysis (OR 1.47, 95% CI 0.78 to 2.77; P = 0.232) ( Values expressed as n (%), mean ± SD, or median (IQR), unless otherwise noted. Values may not add up due to missing data, missing values >10% are reported. n, numbers; y, years; BMI, body mass index; kg/m2, kilograms per square metre; ACB, Anticholinergic Cognitive Burden scale; VMS, safety management system; 6-CIT, six item cognitive impairment test; IQCODE-N, (Dutch short form) Informant Questionnaire on Cognitive Decline in the Elderly; CRP, C-reactive protein; (m)g, (milli)grams; L, liter; mmol, millimole; μmol, micromole; QTc, QT interval corrected for heart rate; ms, milliseconds.
Reference range values: CCI maximum score 29, higher score reflects greater comorbidity; Katz ADL total scores range from 0 (complete independence) to 6 (complete dependence); 6-CIT sum score 0-28; IQCODE-N informant scores for each item range from 1 'much improved' to 5 'much worse' with 3 representing 'no change'; albumin 35-55 g/L; creatinine 45-100 (male), 45-80 (female) μmol/L; CRP < 10 mg/L; potassium 3. Values expressed as n (%), mean ± SD or median (IQR), unless otherwise noted. Values may not add up due to missing data, only missing values >10% are noted. Side effects noted within the first 8 days after initiation of study treatment. *Missing values for DRS-R-98 53.7%. n, number; MD, mean differences; d, days; DRS-R-98, Delirium Rating Scale Revised 98, 13 severity items individually scored 0-3 points, 1.5 points are counted when an item could not be assessed; h, hours; mg, milligrams; d, days; QTc, QT interval corrected for heart rate; ms, milliseconds; ACS, acute coronary syndrome; EPS, extrapyramidal symptoms; TIA, Transient Ischaemic Attack. a Within 7-day study period. b Maximum DOS score per shift, average/24 h computed if three scores per 24 h were available. c For those patients who were living at home with or without additional care prior to index admission and not lost to follow-up at 3 months (n = 141) or 6 months (n = 130). d For any cause after discharge from hospital (index admission) for patients not lost to follow-up at 3 months (n = 161) and 6 months (n = 146 were the mean number of treatment days and average daily dose received. There were no significant differences between groups in clinical endpoints. Adverse events were uncommon (0-5%) and did not differ between groups ( Table 2) .
Discussion
In this multi-centre, randomised, double-blind, placebocontrolled trial no significant positive effect of oral haloperidol prophylaxis on delirium incidence in at risk acutely admitted older patients was demonstrated. In addition, results on clinical endpoints were comparable with the placebo group. There were no significant treatment-limiting side effects. Previous placebo-controlled RCTs on haloperidol prophylaxis for in-hospital delirium prevention in predominantly elective surgical populations also do not unequivocally demonstrate positive effects [15, [25] [26] [27] , not even in participants with Mini-Mental State Examination (MMSE) scores below 25 [15, 27] . Furthermore, none of these studies report significant haloperidol-related side effects [15, [25] [26] [27] . Our study is one of the first to focus on acute hospital admissions, including a large group of older people (≥80 years) mostly non-surgical patients.
Naturally, our study has certain limitations that warrant discussion. First, we did not reach the intended sample size. Inclusion rates were mainly limited by the strict exclusion criteria incorporated to ensure subject safety and time available for enrolment was eventually limited by restricted financial resources as this was an investigator-initiated multi-centre trial. Nonetheless, overall delirium incidence (16.9%) was what could be expected in an acutely admitted older patient population [28] and the statistical power of our current sample (59%) is in our opinion acceptable. Second, only subjects with baseline VMS delirium risk score ≥1 were eligible to prevent unnecessary exposure to haloperidol. This tool has shown to predict incident delirium with 82% sensitivity and 62% specificity [29] . However, this instrument consists of three relatively subjective questions and therefore may not be compared to the more objective and laborious delirium risk stratification tool used in a previous trial [15] . Because of its content, we did not consider this tool used in a previous trial feasible for use in an acute care setting. Because subjects were screened within 24 h of admission, this could have resulted in inclusion of patients at risk for delirium due to a single positive score on the screening tool item 'self-care assistance within the past 24 hours' while functionally independent before admission. Although we did not specifically address ADL status in the weeks prior to admission for comparison, almost half of our study population reported to have memory complaints and almost a third had previously experienced delirium, both independent predictors for delirium during admission [29] . Third, as resources for investigator-initiated trials are always limited, the conduct of this multi-centre trial was challenging and largely depended on intrinsic motivation and efforts of participating site staff. Although obtaining DOSS scores three times daily is part of standard hospital care for older at risk patients since implementation of the VMS programme in the Netherlands, our study also shows that there is room for improvement in guideline adherence, especially in acutely admitted patients [30] . Despite repeated comprehensive instructions on study procedures for all personnel involved, incomplete DOSS and DRS-R-98 scores were common, as previous studies also noted [24, 30] . As a result, assessment of delirium duration and severity mainly depended on clinical observations in addition to these scores. Although the DOSS has been validated and used in studies for this purpose [24] , this may have diminished the accuracy of assessment of delirium severity and our results should therefore be interpreted with caution. Fourth, patients with significant cognitive impairment or dementia were not eligible for study inclusion which may have resulted in the exclusion of patients who were most likely at great risk for delirium. This may limit the generalisability of our results.
Conclusions
Our results demonstrate that in this acutely admitted older in-hospital population, preventive treatment with oral haloperidol does not lower delirium incidence during the first 7 days of admission. Also, haloperidol had no influence on clinical outcomes such as mortality and hospital LOS. Therefore, in our opinion, prophylactic haloperidol should not be used for prevention of hospital-associated delirium in an older acutely admitted at risk patient population.
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Key points
• There is a growing interest in haloperidol use for delirium prevention, although evidence is limited.
• Placebo-controlled trials in surgical patients report contradicting findings.
• We investigated the efficacy of haloperidol prophylaxis for delirium prevention in acutely admitted at risk older patients.
• Compared to placebo, no differences in delirium incidence or relevant clinical outcomes were noted.
• Our results do not support the use of prophylactic haloperidol for delirium prevention in these patients.
